EGFR and squamous cell lung carcinoma: Unlike lung adenocarcinoma (LUAD), patients with lung squamous cell carcinoma (LUSC) have not benefited from targeted therapies such as EGFR tyrosine-kinase inhibitors (TKIs) due to the low mutation rate [2].